Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns a combination with pemetrexed and platinum for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma
Evidence for efficacy is based on the results from the AUGMENT-101 study
Findings from the CheckMate 8HW study
Findings from the STARGLO study
Findings from the PEACE-1 study
It is indicated in combination with amivantamab for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations
Evidence for efficacy is based on the results from the FELIX study
Findings from the SU2C-SARC032 study
Findings from the OPERA study
Findings from the INAVO120 study
It is intended for the treatment of patients with solid tumours with NTRK gene fusion and patients with ROS1-positive advanced NSCLC
Evidence for efficacy is based on the results from the ASC4FIRST study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
